Androgen-sensitive epilepsy, migraine, sleep apnea, polycythemia or fluid over-load need to be considered. Competitive athletes should be warned regarding the risks of disqualification. ART should be initiated with IM injections of testosterone esters, 250 mg every 2 weeks. Maintenance requires tailorin...
For the prostate cancer indication only, precertification of gonadotropin-releasing hormone products (also called luteinizing hormone-releasing hormone agents) is required of all Aetna participating providers and members in applicable plan designs. For precertification of these products for prostate cancer, ...
Chemohormonal therapy in metastatic hormone- sensitive prostate cancer: Long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J. Clin. Oncol. 2018, 36, 1080–1087. [CrossRef] 14. Fizazi, K.; Tran, N.; Fein, L.; Matsubara, N.; Rodriguez-Antolin, A.; Alekseev,...
Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. Cancer 2009, 115, 981–987. [CrossRef] [PubMed] 28. Kitagawa, Y.; Ueno, S.; Izumi, K.; Mizokami, A.; ...
As described before, GH therapy improves arterial hypertension in GHD patients by acting on the vascular smooth muscle ATP-sensitive potassium (KATP) channel, and on the lipid profile with independence of IGF-I. A dysfunction of eNOS in both endothelial cells and platelets has been found in ...